FASN and cancer: At present, only TVB-2640 is the first clinically tested selective and potent FASN inhibitor, and is being included in the clinical trial (ClinicalTrials.gov: NCT02223247) of paclitaxel combined cohorts in cancer treatment (Patel et al., 2015).